JP2003523207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003523207A5 JP2003523207A5 JP2001561030A JP2001561030A JP2003523207A5 JP 2003523207 A5 JP2003523207 A5 JP 2003523207A5 JP 2001561030 A JP2001561030 A JP 2001561030A JP 2001561030 A JP2001561030 A JP 2001561030A JP 2003523207 A5 JP2003523207 A5 JP 2003523207A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- liv
- polypeptide
- binds
- atcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 description 47
- 102000004196 processed proteins & peptides Human genes 0.000 description 47
- 108090000765 processed proteins & peptides Proteins 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 101000685848 Homo sapiens Zinc transporter ZIP6 Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 102100023144 Zinc transporter ZIP6 Human genes 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000003145 cytotoxic factor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004565 tumor cell growth Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 201000003804 salivary gland carcinoma Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 208000012991 uterine carcinoma Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17795100P | 2000-01-25 | 2000-01-25 | |
| US60/177,951 | 2000-01-25 | ||
| US19576100P | 2000-04-10 | 2000-04-10 | |
| US60/195,761 | 2000-04-10 | ||
| PCT/US2001/002622 WO2001055178A2 (en) | 2000-01-25 | 2001-01-25 | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003523207A JP2003523207A (ja) | 2003-08-05 |
| JP2003523207A5 true JP2003523207A5 (hr) | 2008-05-22 |
Family
ID=26873811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001561030A Withdrawn JP2003523207A (ja) | 2000-01-25 | 2001-01-25 | Ｌｉｖ−１関連タンパク質、それをコードするポリヌクレオチド、及び癌の治療へのその利用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7285382B2 (hr) |
| EP (1) | EP1263780A2 (hr) |
| JP (1) | JP2003523207A (hr) |
| KR (1) | KR20020073181A (hr) |
| AU (1) | AU3458401A (hr) |
| CA (1) | CA2395832A1 (hr) |
| IL (2) | IL150592A0 (hr) |
| MX (1) | MXPA02007190A (hr) |
| WO (1) | WO2001055178A2 (hr) |
| ZA (1) | ZA200205191B (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6762020B1 (en) | 1999-03-15 | 2004-07-13 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
| US20040141983A1 (en) * | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
| AU2002324451A1 (en) * | 2001-06-21 | 2003-01-08 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| ATE554164T1 (de) | 2002-02-20 | 2012-05-15 | Sysmex Corp | Primer für nukleinsäureamplifikation bei der detektion von haushaltsgen-mrna und testverfahren unter verwendung der primer |
| AU2004207538A1 (en) * | 2003-01-27 | 2004-08-12 | Biogen Idec Ma Inc. | Compositions and methods for treating cancer using IGSF9 and LIV-1 |
| WO2004067564A2 (en) * | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| CA2541709C (en) | 2003-11-13 | 2013-06-04 | California Pacific Medical Center | Anti-pecam therapy for metastasis suppression |
| FR2863275B1 (fr) * | 2003-12-09 | 2007-08-10 | Biomerieux Sa | Procede pour le diagnostic/pronostic du cancer du sein |
| US20080070836A1 (en) * | 2003-12-26 | 2008-03-20 | Toshio Hirano | Emt-Inducing Agents |
| US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| WO2005095942A1 (ja) * | 2004-03-30 | 2005-10-13 | Riken | レーザーアブレーションを用いた生体試料の分析方法およびその装置 |
| WO2006069403A2 (en) | 2004-12-22 | 2006-06-29 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
| TW200813231A (en) * | 2006-04-13 | 2008-03-16 | Novartis Vaccines & Diagnostic | Methods of treating, diagnosing or detecting cancer |
| US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
| WO2008150485A2 (en) * | 2007-05-29 | 2008-12-11 | Wyeth | Erbb2 binding proteins and use thereof |
| US8097423B2 (en) * | 2007-07-30 | 2012-01-17 | Institute Of Virology | MN/CA IX and breast cancer therapy |
| US20100092894A1 (en) * | 2008-10-14 | 2010-04-15 | Weihong Liu | Bottom Antireflective Coating Compositions |
| US8361744B2 (en) | 2009-11-05 | 2013-01-29 | Genentech, Inc. | Methods and composition for secretion of heterologous polypeptides |
| EP2606349A4 (en) * | 2010-08-20 | 2014-04-30 | Univ Jefferson | AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY |
| NZ611468A (en) | 2010-12-06 | 2015-06-26 | Seattle Genetics Inc | Humanized antibodies to liv-1 and use of same to treat cancer |
| WO2013112881A1 (en) | 2012-01-27 | 2013-08-01 | Thomas Jefferson University | Mct protein inhibitor-related prognostic and therapeutic methods |
| US10022372B2 (en) | 2013-04-19 | 2018-07-17 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
| WO2015139046A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| MA45324A (fr) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| ATE155813T1 (de) | 1989-05-19 | 1997-08-15 | Genentech Inc | Her2 extrazellulare domäne |
| CA2132500A1 (en) * | 1994-09-20 | 1996-03-21 | David Lockwood Manning | Methods for predicting the behaviour of breast tumours |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2315435T3 (es) | 1996-08-12 | 2009-04-01 | Celgene Corporation | Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas. |
| IL129354A0 (en) | 1996-10-18 | 2000-02-17 | Genentech Inc | Anti-ErbB2 antibodies |
| US5860935A (en) | 1996-10-29 | 1999-01-19 | Novid Inc. | Game apparatus and method for monitoring psycho-physiological responses to questions |
| WO1998050555A2 (en) | 1997-05-06 | 1998-11-12 | Human Genome Sciences, Inc. | Enterococcus faecalis polynucleotides and polypeptides |
| WO1999006673A1 (en) | 1997-07-30 | 1999-02-11 | Eg & G Sealol, Inc. | Improved brush seal and method of making same |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| DE19813839A1 (de) | 1998-03-20 | 1999-09-23 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Brusttumorgewebe |
| CA2324494A1 (en) | 1998-03-27 | 1999-09-30 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
| AU1316200A (en) | 1998-10-15 | 2000-05-01 | Chiron Corporation | Metastatic breast and colon cancer regulated genes |
| US6579973B1 (en) | 1998-12-28 | 2003-06-17 | Corixa Corporation | Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| WO2000058336A1 (en) | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | 50 human secreted proteins |
| US6762020B1 (en) * | 1999-03-15 | 2004-07-13 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
| US20040141983A1 (en) * | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
| WO2000055629A2 (en) | 1999-03-15 | 2000-09-21 | Eos Biotechnology, Inc. | Methods of diagnosing and treating breast cancer |
| US6649342B1 (en) * | 1999-03-15 | 2003-11-18 | Eos Biotechnology, Inc. | Methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators |
| EP1212343A4 (en) | 1999-09-03 | 2004-11-03 | Human Genome Sciences Inc | 52 HUMAN SECRETED PROTEINS |
| US6780586B1 (en) * | 1999-11-29 | 2004-08-24 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
| US6750013B2 (en) * | 1999-12-02 | 2004-06-15 | Protein Design Labs, Inc. | Methods for detection and diagnosing of breast cancer |
| AU2001283463A1 (en) * | 2000-08-18 | 2002-03-04 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer and screening for cancer modulators |
| AU2002245317A1 (en) * | 2001-01-24 | 2002-08-06 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
-
2001
- 2001-01-25 KR KR1020027009510A patent/KR20020073181A/ko not_active Application Discontinuation
- 2001-01-25 AU AU34584/01A patent/AU3458401A/en not_active Abandoned
- 2001-01-25 CA CA002395832A patent/CA2395832A1/en not_active Abandoned
- 2001-01-25 EP EP01906709A patent/EP1263780A2/en not_active Withdrawn
- 2001-01-25 IL IL15059201A patent/IL150592A0/xx unknown
- 2001-01-25 MX MXPA02007190A patent/MXPA02007190A/es not_active Application Discontinuation
- 2001-01-25 WO PCT/US2001/002622 patent/WO2001055178A2/en active Application Filing
- 2001-01-25 US US10/182,033 patent/US7285382B2/en not_active Expired - Fee Related
- 2001-01-25 JP JP2001561030A patent/JP2003523207A/ja not_active Withdrawn
-
2002
- 2002-06-27 ZA ZA200205191A patent/ZA200205191B/xx unknown
-
2005
- 2005-05-02 US US11/120,399 patent/US7982015B2/en not_active Expired - Fee Related
-
2006
- 2006-10-05 US US11/538,881 patent/US7691566B2/en not_active Expired - Fee Related
-
2009
- 2009-11-25 IL IL202332A patent/IL202332A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003523207A5 (hr) | ||
| KR102618312B1 (ko) | 항muc16 항체 및 그의 용도 | |
| TWI432452B (zh) | 針對ｈｅｒ-３之抗體類及其用途 | |
| JP5601836B2 (ja) | Ｔｅｓ７およびｔｅｓ７に結合する抗体 | |
| US8753829B2 (en) | Monoclonal antibodies against HER2 antigens, and uses therefor | |
| US7399469B2 (en) | Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer | |
| JPH04503012A (ja) | Ｃ―ｅｒｂＢ―２外部ドメイン：ＧＰ７５ | |
| US20030086929A1 (en) | Treatment of prostate cancer by inhibitors of ATP synthase | |
| JP2010537671A5 (hr) | ||
| MX2011004684A (es) | Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor. | |
| KR20080059449A (ko) | 치료용 약제 | |
| CA2605745A1 (en) | Cancer specific pcna isoform binding antibodies and uses thereof | |
| CN106146664B (zh) | 针对肾相关抗原1的抗体及其抗原结合片段 | |
| Keydar et al. | Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens. | |
| SK282649B6 (sk) | Protilátka proti CD44v6, hybridómová bunková línia, molekula protilátky a jej použitie | |
| CN115920078A (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 | |
| CA2355870A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
| KR100473824B1 (ko) | 상피종의진단및치료방법 | |
| KR20100034720A (ko) | 피에이유에프(ｐａｕｆ) 특이적인 인간 단일클론항체, 이를 포함하는 암 치료용 조성물, 이를 이용하는 암의 진단방법 | |
| JPWO2010098503A1 (ja) | 間質性肺炎治療剤 | |
| NZ233147A (en) | Retinoblastoma gene product antibodies and their use in assays for tumor cells | |
| CN113801231A (zh) | 抗dog-1抗体或其抗原结合片段及其用途 | |
| CN106456809B (zh) | 靶向B细胞受体复合物膜结合IgM的抗体及其用途 | |
| CN113321730B (zh) | Cldn18.2抗体及其应用 | |
| WO2024012395A1 (en) | Anti-mesothelin antibodies |